Stage 1: History & Presentation (Timestamp: 2-3 Weeks Prior to Admission)
A 73-year-old active female retired executive residing in North India (Delhi NCR) presents to the emergency department with a 3-week history of progressive cognitive slowing, waxing and waning confusion, intermittent high-grade fevers (38.0–38.8°C), persistent headache, and severe anorexia.
HPI:
- 3 Weeks Ago: Was fully independent (active in gardening and household chores). Developed subtle memory gaps, apathy, and low-grade evening fevers.
- 1 Week Ago: Disorientation worsened; became confused, wandering at home, with severe headache and lethargy. Admitted to a local nursing home and empirically started on IV Ceftriaxone, Vancomycin, and Ampicillin for suspected acute bacterial meningitis.
- ER Presentation: Transferred to a tertiary neuro-ICU due to lack of improvement, persistent fevers, and progressive stupor despite 48 hours of broad-spectrum antibacterial coverage.
PMH: Hypertension, T2D (controlled). Remote childhood history of residing in rural North India. No active TB contacts reported by family.
Hello, Chief Resident here.
Key Findings: A 73-year-old female in North India presenting with subacute (3-week) febrile encephalopathy, severe headache, and cognitive decline, unresponsive to 48 hours of broad-spectrum antibacterial therapy (including Listeria coverage).
Differential Diagnoses:
1. Tuberculous Meningitis (TBM) (50%): Subacute course, high local endemicity, non-response to standard antibiotics.
2. Fungal Meningitis (e.g., Cryptococcal) (25%): Subacute presentation in an elderly diabetic patient with persistent headache/fever.
3. Viral Encephalitis (HSV/VZV) (15%): Progressive cognitive decline, confusion, and fevers; requires empiric cover.
4. Autoimmune/Paraneoplastic Encephalitis (10%): Subacute encephalopathy, memory gaps, and refractory symptoms.
Recommended Prioritised Tests:
1. Lumbar Puncture (CSF): Opening pressure, cell count, protein/glucose, GeneXpert MTB/RIF, Cryptococcal Antigen, AFB/Fungal stains, and viral PCR panel (HSV/VZV).
2. Contrast-Enhanced Brain MRI: Evaluate for basal meningeal enhancement, tuberculomas, strokes, or temporal lobe hyperintensities.
3. CT Chest/Abdomen: Assess for primary focus of tuberculosis or underlying malignancy.
4. CSF/Serum Autoimmune Encephalitis Panel.
Next Steps: Empirically add IV Acyclovir and consider anti-tubercular therapy (ATT) with high-dose dexamethasone pending CSF results.
Hello Attending Consultant here
Top 3 DDx:
1. Tuberculous meningitis (basal exudates, endemicity, steroid-responsive window)
2. Cryptococcal meningitis (diabetes, subacute ICP elevation)
3. Partially treated bacterial/Listeria or scrub typhus (regional rickettsial overlap)
Critique/Improvements (6 points):
1. Defer empiric ATT/dexamethasone until CSF obtained—risk of diagnostic obscuration; start only if LP delayed >6h or high pretest probability with hydrocephalus.
2. Add serum/CSF CrAg and India ink immediately; cryptococcal IRIS risk if steroids given blindly.
3. Include scrub typhus serology/PCR and Weil-Felix—North India monsoon/post-monsoon encephalitis mimic.
4. MRI prioritise CISS/FIESTA sequences for basal meninges + DWI for infarcts; avoid delay for CT body if neuro-imaging first.
5. Hold acyclovir if MRI lacks temporal changes and CSF RBC/PCR pending—reduce nephrotoxicity in elderly.
6. Quantiferon/TB ELISPOT + HIV serology essential; childhood rural exposure elevates latent TB reactivation risk.
7. Monitor Na+/osmolality closely—SIADH common in TBM; fluid restriction vs hypertonic strategy early.
Hello, Expert Clinician here.
Best unifying diagnosis: Tuberculous meningitis (TBM) — subacute febrile encephalopathy with headache and stupor in a TB-endemic elderly woman, failing pyogenic coverage, is classic. Childhood rural exposure adds latent-reactivation risk.
Top differentials:
- Cryptococcal meningitis — fits diabetes, subacute headache/fever; CrAg will rapidly exclude.
- HSV encephalitis — cognitive decline fits, but high fevers + 3-week tempo less typical; MRI temporal signal/PCR decides.
- Partially treated bacterial (incl. Listeria) — covered empirically; no response argues against.
- Scrub typhus meningoencephalitis — regional, but eschar/absent and headache less prominent.
Key pivot: Failure to improve on ceftriaxone/vancomycin/ampicillin converts a "bacterial meningitis" framing into subacute basal meningitis (TB/fungal) — this reframing must happen before irreversible hydrocephalus or stroke.
Most important next move: Immediate MRI brain (basal enhancement, hydrocephalus, infarcts) followed by LP — record opening pressure; send cell count, protein/glucose, GeneXpert Ultra (centrifuged CSF), CrAg, fungal/AFB studies, HSV PCR. If TBM suspicion remains high, start ATT + dexamethasone promptly — steroids reduce mortality.
Teaching pearl: In endemic regions, a lymphocytic CSF with very high protein, low glucose, and basal enhancement is TBM until proven otherwise — treat empirically rather than wait for microbiologic confirmation, which is often delayed or negative.
Stage 2: Physical Examination & Initial Lumbar Puncture (Timestamp: Admission / Day 1)
Physical Exam: T 38.6°C, HR 98 bpm, BP 132/74 mmHg, SpO2 97% room air. Stuporous, opens eyes to pain, oriented x 1. Marked nuchal rigidity (meningismus present, positive Kernig's sign). Pupil reactivity normal; no focal cranial nerve deficits or limb weakness initially.
Initial Lumbar Puncture (CSF Analysis under Antibiotics):
- Opening Pressure: Severely Elevated at 50 cm H2O (intracranial hypertension).
- CSF Cell Count: WBC 517 cells/µL (85% Lymphocytes, 15% PMNs) (lymphocytic pleocytosis).
- CSF Chemistry: Profound Hypoglycorrhachia (Glucose 17 mg/dL) (CSF:Serum glucose ratio <0.2); Undetectably High CSF Protein (>200 mg/dL).
- CSF Microbiology & PCR: Gram stain negative, Cryptococcal Ag negative, HSV 1/2, VZV, Enterovirus PCR negative. Biofire multiplex panel negative. ADA -14 .CBNAAT - negative.
Neuroimaging & Chest CT:
- MRI Brain: Motion artifact; subtle right parahippocampal T2/FLAIR hyperintensity and basilar meningeal enhancement.
- CT Chest: Old calcified hilar and apical granulomas; no active pulmonary infiltrates.
Hello, Chief Resident here.
Updated Key Findings: Severely elevated intracranial pressure (50 cm H2O), lymphocytic pleocytosis (85%), profound hypoglycorrhachia (17 mg/dL), protein >200 mg/dL, and basilar meningeal enhancement. Initial GeneXpert, ADA, and CrAg are negative.
Differential Diagnoses:
1. Tuberculous Meningitis (TBM) (65%): Clinical picture, basal enhancement, and CSF profile remain overwhelmingly consistent with TBM. GeneXpert/ADA have known sensitivity limits.
2. Fungal Meningitis (e.g., Aspergillus, Histoplasma) (15%): Marked hypoglycorrhachia, severe ICP elevation, and basilar involvement strongly support a fungal process.
3. Atypical/Subacute Infection (e.g., Scrub Typhus, Brucellosis, Listeria) (10%): Regional endemicity and subacute presentation warrant consideration despite prior coverage.
4. Non-Infectious Meningitis (Carcinomatous/Neurosarcoidosis) (10%): Profoundly low glucose and high protein with basal enhancement can mimic TBM.
Prioritised Next Steps:
1. Immediate ICP Control: Perform repeat therapeutic LP or consult Neurosurgery for lumbar drain/EVD (OP 50 cm H2O poses severe herniation risk).
2. Empiric Treatment: Start 4-drug ATT and IV Dexamethasone immediately without awaiting further culture results.
3. Repeat Large-Volume LP (Centrifuged CSF): Send for GeneXpert Ultra, fungal/AFB cultures, and cytology.
4. Serology Panel: Scrub typhus IgM and Brucella serology.
Hello Attending Consultant here
Top 3 DDx:
1. Tuberculous meningitis (classic CSF triad + basal enhancement + calcified granulomas; Xpert/ADA false-neg common)
2. Fungal meningitis (Histoplasma/Coccidioides; profound hypoglycorrhachia + OP 50)
3. Carcinomatous meningitis (elderly; cytology pending)
Critique/Improvements (6 points):
1. Start ATT + dex now—CSF profile + endemicity + negative pyogenic/viral workup meets high-probability TBM criteria; delay risks vasculitic stroke.
2. Prioritize urgent EVD over serial LPs for OP 50—sustained drainage prevents herniation and allows daily CSF sampling.
3. Demand GeneXpert Ultra on ≥5–10 mL centrifuged CSF + MGIT culture; single negative CBNAAT insufficient.
4. Add serum/CSF Histoplasma/Cryptococcal Ag (repeat) and β-D-glucan; India ink alone misses.
5. MRI with contrast + MRA/MRV once stabilized—map infarcts, hydrocephalus, venous thrombosis.
6. Hold scrub/Brucella serology as low-yield given glucose <20 and protein >200; prioritize cytology + flow for malignancy.
7. Strict Na+ q6h + acetazolamide trial post-EVD; SIADH/cerebral salt wasting dichotomy critical.
Hello, Expert Clinician here.
Best unifying diagnosis: Tuberculous meningitis. The CSF triad — lymphocytic pleocytosis, glucose 17 (ratio <0.2), protein >200 — plus basilar enhancement, calcified hilar/apical granulomas, and endemic exposure is virtually pathognomonic. Negative CBNAAT/ADA does not exclude TBM; Xpert sensitivity is only ~50–70%, ADA less.
Top differentials:
- Fungal meningitis (Histoplasma) — profound hypoglycorrhachia and high OP fit; CrAg negative, but send Histoplasma Ag/β-D-glucan.
- Carcinomatous meningitis — age and CSF chemistry fit; cytology (×3 large-volume taps) mandatory.
- HSV — parahippocampal signal noted, but PCR negative and CSF profile argues strongly against.
Key pivot: Microbiology-negative but phenotype-positive TBM. Waiting for confirmation risks vasculitic infarction and herniation from OP of 50 — treat on clinical-radiologic-CSF probability.
Most important next moves (parallel): (1) Start 4-drug ATT + IV dexamethasone now; (2) urgent EVD/lumbar drain for ICP crisis; (3) repeat large-volume centrifuged CSF for Xpert Ultra, MGIT culture, fungal studies, cytology; (4) monitor sodium closely.
Teaching pearl: In TBM, the CSF formula is the test — hypoglycorrhachia this profound with basal enhancement demands empiric therapy; a negative GeneXpert should never override it.
Stage 3: Hospital Course & Neurological Collapse (Timestamp: Hospital Days 3-7)
ICU Course & Interventions:
- Emergency placement of an External Ventricular Drain (EVD) for severe intracranial hypertension (opening pressure 50 cm H2O). Initial EVD placement produced temporary clearing of sensorium and CSF pressure control.
- Hospital Day 4-5: Experienced acute neurological deterioration—developed right-sided hemiparesis, progressive central hypoventilation requiring mechanical ventilation, and basilar artery vasculitis on repeat imaging.
Diagnostic Workup: Fungal cultures, CSF VDRL, serum Quantiferon-TB Gold, and autoimmune encephalitis panels inconclusive or pending. High-dose IV Dexamethasone initiated empirically for severe basilar meningoencephalitis.
Hello, Chief Resident here.
Updated Key Findings: Subacute febrile encephalopathy progressing to acute brainstem and corticospinal failure (central hypoventilation, right hemiparesis) despite initial EVD decompression. Radiographic confirmation of basilar artery vasculitis.
Differential Diagnoses:
1. Tuberculous Meningitis with Basilar Vasculitis & Brainstem Stroke (75%): Classic complication; thick basilar exudates encase brainstem perforators, causing vasculitic infarction and central respiratory failure.
2. Fungal Angioinvasive Meningitis (Aspergillus/Cryptococcus) (15%): Capable of severe basilar inflammation, angioinvasion, and secondary arterial thrombosis.
3. CNS Autoimmune/Paraneoplastic Vasculitis (5%): Severe subacute basilar inflammation with vascular occlusion.
4. Listerial Rhombencephalitis (5%): Subacute brainstem involvement, though less likely given prior ampicillin coverage.
Prioritised Next Steps:
1. Initiate Full-Dose ATT Immediately: Must be combined with high-dose steroids (consider adding Linezolid or Fluoroquinolones for superior CNS penetration).
2. MRI Brain with MRA & Diffusion-Weighted Imaging: Assess basilar territory ischemia, brainstem involvement, and stenosis severity.
3. EVD CSF Diagnostics: Send high-volume centrifuged CSF for GeneXpert Ultra, MGIT culture, and fungal markers (Beta-D-Glucan, Galactomannan).
4. Hemodynamic Optimization: Target higher mean arterial pressures (MAP) to maintain cerebral perfusion pressure (CPP) across vasculitic segments.
5. CSF Cytology (3rd sample): Rule out carcinomatous/lymphomatous meningitis.
Hello Attending Consultant here
Top 3 DDx:
1. TBM with basilar arteritis & perforator infarcts (exudate-mediated; classic Day 4–7 deterioration)
2. Angio-invasive mold (Aspergillus) meningitis
3. Carcinomatous meningitis with vasculopathy
Critique/Improvements (6 points):
1. ATT + dex already overdue—escalate immediately to HRZE + linezolid; do not await pending Quantiferon.
2. Add aspirin 150 mg + nimodipine for TBM vasculitis; MAP 85–95 mmHg via pressors to defend CPP.
3. Urgent MRA/MRV + DWI now—quantify basilar stenosis and brainstem infarct burden; CTA if MRI delayed.
4. EVD CSF: ≥10 mL centrifuged for Xpert Ultra + MGIT + galactomannan/β-D-glucan; repeat cytology ×2.
5. Drop Listeria/autoimmune priority—CSF formula + basilar vasculitis overrides; steroids already cover.
6. Prepare for tracheostomy & PEG; central hypoventilation signals irreversible medullary involvement.
7. Serial Na+/osmolality q4h—CSW vs SIADH dictates fludrocortisone vs restriction.
Hello, Expert Clinician here.
Best unifying diagnosis: Tuberculous meningitis complicated by basilar arteritis with perforator infarction — the classic Day 3–7 "paradoxical" deterioration. Thick basilar exudates strangulate brainstem perforators, producing hemiparesis and central hypoventilation exactly as seen.
Top differentials:
- Angioinvasive aspergillosis — vasculitis fits, but negative galactomannan/CrAg and subacute tempo favor TB; send EVD CSF galactomannan/β-D-glucan.
- Carcinomatous meningitis — CSF chemistry overlaps; third cytology pending.
- Autoimmune vasculitis — steroids partly cover, but CSF formula is diagnostic of chronic infection.
Key pivot: Neurological collapse after ICP control is not treatment failure — it is the expected vascular complication of TBM, occurring on or off therapy, and mandates intensified (not abandoned) treatment.
Most important next moves: Continue/escalate ATT (HRZE + linezolid for CNS penetration) with dexamethasone; add aspirin (reduces stroke in TBM); maintain MAP 85–95 to defend perfusion across stenosed segments; MRI/MRA-DWI to quantify infarct burden; EVD CSF for Xpert Ultra/MGIT + fungal markers.
Teaching pearl: In TBM, steroids prevent death but not stroke — adjunctive aspirin plus aggressive CPP support during the vasculitic window is where morbidity is won or lost.
Stage 4: Advanced Metagenomic Sequencing & Molecular Identification (Timestamp: Hospital Day 8 / Research Testing)
Given the refractory lymphocytic meningoencephalitis with severe hypoglycorrhachia and negative routine PCRs, advanced diagnostic testing was performed:
- Metagenomic Next-Generation Sequencing (mNGS) of CSF: Sequencing of cell-free DNA/RNA from stored CSF identified high-abundance specific sequence reads mapping to Mycobacterium tuberculosis complex (MTB).
- Host-Response Machine Learning Profiling: Host expression model predicted an atypical mycobacterial/bacterial meningeal pathogen.
Hello, Chief Resident here.
Updated Key Findings: Definitive molecular confirmation of Mycobacterium tuberculosis complex (MTB) via CSF mNGS, establishing the diagnosis of Tuberculous Meningitis (TBM) complicated by basilar arteritis, severe intracranial hypertension, and brainstem ischemia.
Differential Diagnoses:
1. Tuberculous Meningitis (TBM) with Basilar Vasculitis (95%): Confirmed by mNGS; perfectly matches the subacute course, classic CSF profile, and vasculitic complications.
2. Drug-Resistant TBM (MDR-TB) (3%): High index of suspicion needed in severe presentation from an endemic region.
3. Secondary Nosocomial/Fungal Superinfection (2%): Potential risk given prolonged EVD placement and high-dose steroid administration.
Prioritised Next Steps:
1. Intensified ATT Regimen: Continue first-line ATT (HRZE) and add Linezolid and Moxifloxacin for superior CNS penetration and potential drug resistance coverage.
2. Steroid Protocol: Continue IV Dexamethasone (0.4 mg/kg/day) with a slow 6–8 week taper to reduce basilar exudates and vasculitis.
3. Ischemic Stroke Prophylaxis: Maintain Aspirin (100–150 mg daily) and target MAP 85–95 mmHg to preserve cerebral perfusion.
4. Resistance Profiling: Send CSF cell-free DNA for targeted sequencing/LPA to screen for rpoB (rifampicin) and katG/inhA (isoniazid) resistance.
5. Airway/Nutritional Support: Proceed with tracheostomy and PEG placement given persistent central hypoventilation.
Hello Attending Consultant here
Top 3 DDx:
1. Confirmed TBM with basilar arteritis/infarcts (mNGS-proven; Day 3–7 vascular window)
2. MDR/XDR-TBM (endemic risk; severe phenotype)
3. EVD-related superinfection (bacterial/fungal) atop steroids
Critique/Improvements (6 points):
1. Escalate immediately to intensified CNS regimen (HRZE + linezolid + moxifloxacin); do not await LPA—mNGS already definitive.
2. Obtain rapid molecular DST (Xpert Ultra MTB/RIF or targeted NGS) on EVD CSF for rpoB/katG before adding agents blindly.
3. Continue high-dose dex + aspirin 150 mg; add nimodipine if basilar stenosis persists on MRA.
4. Serial EVD CSF q48h for AFB culture/MGIT + galactomannan to exclude superinfection.
5. MAP 85–100 mmHg + CPP monitoring; avoid hypotension that extends brainstem infarcts.
6. Early trach/PEG + swallow eval; central hypoventilation rarely reverses quickly.
7. Screen household contacts + Quantiferon on family; latent TB cascade now relevant.
Hello, Expert Clinician here.
Best unifying diagnosis: mNGS-confirmed tuberculous meningitis (TBM) with basilar arteritis, perforator infarction, and medullary involvement — the full disease arc is now molecularly validated.
Top differentials (now prognostic, not diagnostic):
- MDR/XDR-TBM — must exclude given severity and endemicity; mortality rises sharply if rifampicin-resistant.
- EVD superinfection — steroids + hardware invite bacterial/fungal coinfection.
- Treatment-emergent paradoxical reaction — relevant during weeks 2–4; currently less likely than ongoing vasculitis.
Key pivot: mNGS converted a probability-based empiric diagnosis into molecular certainty — but crucially, management was already correct before confirmation. The lesson: act on the CSF phenotype; use mNGS to refine (resistance profiling), not to delay.
Most important next moves: (1) Intensified CNS-penetrant regimen — HRZE + linezolid + moxifloxacin; (2) rapid molecular DST (Xpert Ultra/targeted NGS for rpoB, katG, inhA) from EVD CSF; (3) continue dexamethasone with structured 6–8 week taper + aspirin; (4) maintain MAP 85–95 mmHg; (5) tracheostomy/PEG; (6) contact screening.
Teaching pearl: mNGS is transforming CNS infection diagnostics — detecting MTB where CBNAAT failed — but it rewards the clinician who never stopped treating while waiting for the answer.
Stage 5: Final Unifying Diagnosis & Tissue Confirmation (Timestamp: Post-Mortem & Pathology)
Pathology & Autopsy Confirmation:
- Brain Autopsy / Biopsy: Demonstrated severe basilar leptomeningitis, tuberculous vasculitis with secondary ischemic/hemorrhagic infarction, Acid-Fast Bacilli (AFB) positive on Ziehl-Neelsen staining, and a large hemorrhagic cavitary Tuberculoma in the right parahippocampal gyrus.
- Microbiologic Confirmation: CSF mycobacterial culture subsequently grew Mycobacterium tuberculosis (sensitive to first-line ATT).
Final Unifying Diagnosis: Central Nervous System Tuberculosis (CNS Tuberculosis / Tuberculous Meningitis & Parahippocampal Tuberculoma) presenting with subacute lymphocytic meningoencephalitis, severe intracranial hypertension, and basilar vasculitis.
Hello, Chief Resident here.
Updated Key Findings: Post-mortem pathology and culture confirmed pansensitive Mycobacterium tuberculosis causing severe basilar leptomeningitis, tuberculous vasculitis with brainstem/cerebral infarction, and a hemorrhagic parahippocampal tuberculoma.
Final Diagnoses:
1. Definitive CNS Tuberculosis (TBM with Tuberculoma & Vasculitis) (100%): Histopathologically (AFB+) and microbiologically (culture+) proven.
Case Analysis & Key Takeaways:
This tragic case illustrates the natural history of fulminant TBM. The subtle early parahippocampal MRI signal represented an evolving tuberculoma. Despite ICP control via EVD and mNGS identification, basilar arteritis led to fatal brainstem infarction. Negative initial CBNAAT/ADA contributed to early diagnostic uncertainty, reinforcing that negative molecular/enzymatic rapid tests must never override classic CSF formulas (profound hypoglycorrhachia, high protein, lymphocytic pleocytosis) in endemic regions.
Next Steps & Management:
1. Public Health & Contact Tracing: Mandatory IGRA/CXR screening for all household and close contacts.
2. Morbidity & Mortality (M&M) Review: Analyze pre-transfer delays (empiric bacterial coverage without TBM consideration).
3. Institutional Protocol Update: Standardize early mNGS and prompt empiric ATT plus adjunctive dexamethasone and aspirin for suspected subacute basal meningitis.
Hello Attending Consultant here
Top 3 DDx:
1. Confirmed pansensitive TBM + hemorrhagic parahippocampal tuberculoma with basilar vasculitis/infarcts
2. Paradoxical reaction unmasked by steroids (post-ATT)
3. Secondary EVD-related hemorrhage into tuberculoma
Critique/Improvements (6 points):
1. Autopsy validates early empiric ATT+dex+aspirin was mandatory; initial CBNAAT-negative delay was the fatal pivot—protocolize phenotype-driven start <24 h.
2. Hemorrhagic tuberculoma explains Day-1 parahippocampal signal; mandate GRE/SWI sequences on all baseline TBM MRIs.
3. Contact tracing + IGRA mandatory, but add whole-genome sequencing of isolate for cluster detection.
4. M&M must quantify pre-transfer antibiotic window and LP-to-ATT interval as quality metrics.
5. Institutionalize reflex mNGS + Xpert Ultra on centrifuged CSF for any lymphocytic hypoglycorrhachia in endemic zones.
6. Retain linezolid/moxifloxacin escalation pathway even for pansensitive isolates when vasculitis/coma present—CNS PK trumps DST alone.
7. Document CSW vs SIADH trajectory retrospectively; fludrocortisone timing may have altered infarct burden.
Hello, Expert Clinician here.
Best unifying diagnosis: Fully confirmed CNS tuberculosis — pansensitive tuberculous meningitis with hemorrhagic parahippocampal tuberculoma, basilar vasculitis, and secondary ischemic/hemorrhagic brainstem infarction.
Why differentials resolved: Cryptococcus (CrAg negative), HSV (PCR negative, CSF formula wrong), and carcinomatosis (cytology negative) all excluded; autopsy AFB positivity and culture growth seal the diagnosis. The initial "subtle" parahippocampal signal was a tuberculoma masquerading as HSV encephalitis — a critical imaging mimic.
Key pivot: The negative CBNAAT/ADA on Day 1 — this false reassurance allowed precious days of bacterial-only therapy. The classic CSF triad (glucose 17, protein >200, lymphocytic pleocytosis) in an endemic host should have triggered ATT+dexamethasone+aspirin within 24 hours.
Most important next moves (institutional): M&M with pre-transfer delay metrics; protocolize phenotype-driven empiric ATT; reflex mNGS + centrifuged Xpert Ultra; GRE/SWI on baseline MRI; household IGRA contact tracing.
Teaching pearl: In endemic TBM, the CSF chemistry is more sensitive than the molecular test — treat the formula, not the CBNAAT. Delayed steroids and aspirin, not antibiotic resistance, killed this patient through vasculitic stroke.